Comparative look at intravenous iron agents: Pharmacology, efficacy, and safety of iron dextran, iron saccharate, and ferric gluconate

Seminars in Dialysis

Volumn 12, Issue 4, 1999, Pages 243-248

  Sunder Plassmann, Gere ^a,b   Hörl, Walter H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000207678     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139x.1999.99030.x     Document Type: Article

References (20)

1. Sunder-Plassmann G, Hörl WH. Erythropoietin and iron. Clin Nephrol 47:141-157, 1997
2. Danielson BG, Geisser P, Schneider W: Iron Therapy. St. Gallen: Vifor (International) Inc, 1996
3. Hillman RS: Hematopoietic Agents, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., edited by Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. New York: McGraw-Hill, 1996, pp. 1311-1340
4. Fairbanks VF, Beutler E: Iron deficiency, in Williams Hematology, edited by Beutler E, Lichtman MA, Coller BS, Kipps TJ. New York: McGraw-Hill, 1995, pp. 490-509
5. Roe DJ, Harford AM, Zager PG, Wiltbank TB, Kirlin L, Della Valle AM, Van Wyck DB: Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents. Am J Kidney Dis 28:855-860, 1996
6. Kumpf VJ, Holland EG: Parenteral iron dextran therapy. DICP 24:162-166, 1990
7. Wood JK, Milner PFA, Pathak UN: The metabolism of iron-dextran given as a total-dose infusion to iron deficient Jamaican subjects. Br J Haematol 14:119-129, 1968
8. Henderson PA, Hillman RS: Characteristics of iron dextran utilization in mean. Blood 34:357-375, 1969
9. Beamish MR, Davies AG, Eakins JD, Jacobs A, Trevett D: The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol 21:617-622, 1971
10. Davies AG, Beamish MR, Jacobs A: Utilization of iron dextran. Br Med J 1:146-147, 1971
11. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
12. Kotaki M, Uday K, Henriquez M, Blum S, Dave M: Intravenous iron therapy in hemodialysis. [Abstract] J Am Soc Nephrol 7:1452, 1996
13. Sepandj F, Jindal K, West M, Hirsch D: Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:319-322, 1996
14. MacDougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996
15. Kaufman J, Reda D, Goldfarb D, Kleinman J, Vaamonde C: Diagnosis and treatment of iron deficiency in patients on maintenance recombinant human erythropoietin (rHuEPO). [Abstract] J Am Soc Nephrol 7:1450, 1996
16. Suh H, Wadhwa NK: Iron dextran treatment in peritoneal dialysis patients on erythropoietin. Adv Perit Dial 8:464-466, 1992
17. Bastani B, Galley S: Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int 16:646-648, 1996
18. Pecoits-Filho RF, Twardowski ZJ, Kim YL, Khanna R, Moore H, Nolph KD: The absence of toxicity in intraperitoneal iron dextran administration: A functional and histological analysis. Perit Dial Int 18:64-70, 1998
19. Carter TB, Garris AG, Ullian ME: Rusty peritoneal dialysis fluid after intravenous administration of iron dextran. Am J Kidney Dis 27:147-150, 1996
20. Burns DL, Mascioli EA, Bistrian BR: Parenteral iron dextran therapy: a review. Nutrition 11:163-168, 1995